Article
High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine.
Blood - 14 Oct 2010
Bachas Costa, Schuurhuis Gerrit Jan, Hollink Iris H I M, Kwidama Zinia J, Goemans Bianca F, Zwaan C Michel, van den Heuvel-Eibrink Marry M, de Bont Eveline S J M, Reinhardt Dirk, Creutzig Ursula, de Haas Valerie, Assaraf Yehuda G, Kaspers Gertjan J L, Cloos Jacqueline
Abstract excerpt
Although virtually all pediatric patients with acute myeloid leukemia (AML) achieve a complete remission after initial induction therapy, 30%-40% of patients will encounter a relapse and have a dismal prognosis. To prevent relapses, personalized treatment strategies are currently being developed, which target specific molecular aberrations. To determine relevance of established AML type I/II mutations that may...
Topics
- Adolescent
- Base Sequence
- Biomarkers, Tumor
- Child
- Child, Preschool
- Cohort Studies
- DNA Mutational Analysis
- DNA Primers
- DNA, Neoplasm